MX367352B - Metodos para reducir el riesgo de padecer una enfermedad cardiovascular. - Google Patents

Metodos para reducir el riesgo de padecer una enfermedad cardiovascular.

Info

Publication number
MX367352B
MX367352B MX2014008180A MX2014008180A MX367352B MX 367352 B MX367352 B MX 367352B MX 2014008180 A MX2014008180 A MX 2014008180A MX 2014008180 A MX2014008180 A MX 2014008180A MX 367352 B MX367352 B MX 367352B
Authority
MX
Mexico
Prior art keywords
methods
patient
cardiovascular disease
reducing risk
ldl
Prior art date
Application number
MX2014008180A
Other languages
English (en)
Other versions
MX2014008180A (es
Inventor
L Bisgaier Charles
Original Assignee
Gemphire Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemphire Therapeutics Inc filed Critical Gemphire Therapeutics Inc
Publication of MX2014008180A publication Critical patent/MX2014008180A/es
Publication of MX367352B publication Critical patent/MX367352B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos para reducir los niveles de LDL-C en plasma en un paciente que recibe una dosis estable de estatina donde el paciente tiene un nivel de LDL-C mayor que el objetivo de tratamiento. Métodos para reducir el riesgo de un paciente de desarrollar una enfermedad cardíaca coronaria o de tener un evento cardiovascular recurrente donde el paciente está recibiendo una dosis estable de estatina y el paciente tiene un nivel de LDL-C mayor que el objetivo de tratamiento.
MX2014008180A 2012-01-06 2013-01-04 Metodos para reducir el riesgo de padecer una enfermedad cardiovascular. MX367352B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261584002P 2012-01-06 2012-01-06
PCT/US2013/020317 WO2013103842A1 (en) 2012-01-06 2013-01-04 Methods of reducing risk of cardiovascular disease

Publications (2)

Publication Number Publication Date
MX2014008180A MX2014008180A (es) 2014-10-14
MX367352B true MX367352B (es) 2019-08-16

Family

ID=48745439

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008180A MX367352B (es) 2012-01-06 2013-01-04 Metodos para reducir el riesgo de padecer una enfermedad cardiovascular.

Country Status (9)

Country Link
US (2) US10028926B2 (es)
EP (2) EP2800564B1 (es)
JP (2) JP6295205B2 (es)
CN (2) CN104136023A (es)
AU (1) AU2013207423B2 (es)
CA (1) CA2861643C (es)
HK (1) HK1201452A1 (es)
MX (1) MX367352B (es)
WO (1) WO2013103842A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS63430B1 (sr) 2010-10-01 2022-08-31 Modernatx Inc Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
DE12858350T1 (de) 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
US9440754B2 (en) 2012-03-29 2016-09-13 R.P. Scherer Technologies, Llc Three circuit fill system for blow fill seal containers
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2909442A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN111704543A (zh) 2014-11-14 2020-09-25 燿石治疗公司 用于制备α,ω-二羧酸封端的二烷醚的方法和中间体
SG11201707497UA (en) 2015-03-13 2017-10-30 Esperion Therapeutics Inc Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
MA41793A (fr) * 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
MX2018005540A (es) 2015-11-06 2018-11-09 Gemphire Therapeutics Inc Tratamiento de dislipemia mixta.
KR20180115722A (ko) * 2016-02-26 2018-10-23 젬파이어 세러퓨틱스 인코포레이티드 지질-저하 요법에서 동형접합성 가족성 고콜레스테롤혈증을 앓는 환자의 치료
EP3579827A4 (en) * 2017-02-08 2021-01-06 Esperion Therapeutics, Inc. FORMULATIONS OF ASSOCIATIONS OF THREE ACTIVE INGREDIENTS AND METHODS OF TREATMENT OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE
US20180297929A1 (en) * 2017-04-18 2018-10-18 Gemphire Therapeutics Inc. Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor
US20190008779A1 (en) * 2017-05-11 2019-01-10 Gemphire Therapeutics Inc. Gemcabene compositions and methods of use thereof
CN109666727B (zh) * 2018-12-29 2020-11-06 中国药科大学 一种高活性抑制pcsk9表达的微小rna的用途
EP3986860A1 (en) 2019-06-21 2022-04-27 Esperion Therapeutics, Inc. Salt forms of bempedoic acid and methods for using the same
CN113134086B (zh) * 2020-01-20 2024-05-24 深圳市长卿医学研究院 一种降血脂的药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
US20020103252A1 (en) 1997-12-12 2002-08-01 Bisgaier Charles Larry Statin-carboxyalkylether combinations
US6861555B2 (en) 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus
ATE384035T1 (de) 1999-04-01 2008-02-15 Esperion Therapeutics Inc Ether-verbindungen, zusammensetzungen und ihre verwendung
EP1351916A2 (en) 2000-10-11 2003-10-15 Esperion Therapeutics Inc. Ether compounds and compositions for cholesterol management and related uses
US6645170B2 (en) 2001-03-05 2003-11-11 Bioject Medical Technologies, Inc. Simplified disposable needle-free injection apparatus and method
US20040229954A1 (en) * 2003-05-16 2004-11-18 Macdougall Diane Elaine Selective manipulation of triglyceride, HDL and LDL parameters with 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt
US7345190B2 (en) 2003-11-12 2008-03-18 Ssv Therapeutics, Inc. Carnitine conjugates as dual prodrugs and uses thereof
WO2007067817A1 (en) 2005-12-07 2007-06-14 Cv Therapeutics, Inc. Abca1 elevating compounds
MX2009001279A (es) * 2006-08-03 2009-02-11 Tufts College Analogos de niacina no eritematosos, y metodos para utilizar los mismos.

Also Published As

Publication number Publication date
JP2018104452A (ja) 2018-07-05
MX2014008180A (es) 2014-10-14
HK1201452A1 (en) 2015-09-04
US20150005386A1 (en) 2015-01-01
WO2013103842A1 (en) 2013-07-11
JP6295205B2 (ja) 2018-03-14
US20180303779A1 (en) 2018-10-25
EP3735967A1 (en) 2020-11-11
CA2861643A1 (en) 2013-07-11
CA2861643C (en) 2020-10-06
EP2800564A1 (en) 2014-11-12
CN104136023A (zh) 2014-11-05
US10709678B2 (en) 2020-07-14
JP2015503588A (ja) 2015-02-02
AU2013207423B2 (en) 2017-10-12
EP2800564B1 (en) 2020-05-06
CN110025608A (zh) 2019-07-19
EP2800564A4 (en) 2015-07-22
AU2013207423A1 (en) 2014-07-24
US10028926B2 (en) 2018-07-24

Similar Documents

Publication Publication Date Title
MX367352B (es) Metodos para reducir el riesgo de padecer una enfermedad cardiovascular.
EP4487908A3 (en) Methods of treating crohn's disease and ulcerative colitis
MY159353A (en) Pirfenidone treatment for patients with atypical liver function
NZ603319A (en) Diabetes therapy
MX2016000173A (es) Sistemas y metodos para seguimiento y presentacion de datos de terapia para acufenos.
MX2013013809A (es) Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
EP4403213A3 (en) Methods for reducing cardiovascular risk
WO2012093258A3 (en) Irf5- related treatment and screening
PH12014501880A1 (en) Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
MX2014001823A (es) Combinaciones de corroles y estatinas.
MX2013003903A (es) Nuevos tratamientos de infeccion por el virus de hepatitis c.
PH12019501028A1 (en) Medicinal complex for treating type 2 diabetes and diabetic dyslipidemia
HK1200731A1 (en) Diethyl- [6- (4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl) - naphthalen-2-yl-methyl] -ammonium chloride for use in the treatment of muscular dystrophy
MX358512B (es) Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva.
UA50950U (ru) Способ лечения больных острым коронарным синдромом с учетом генотипа
RU2010100736A (ru) Способ хирургического лечения щитовидной железы
UA107786C2 (ru) Способ оценки эффективности лечения s-амплодипина больных ишемической болезнью сердца с стенокардией и артериальной гипертензией с нарушением диастолической функции левого желудочка по "гипертрофическом" типа
UA107787C2 (ru) Способ оценки эффективности лечения s-метопрололом больных ишемической болезнью сердца с стенокардией и артериальной гипертензией с нарушением диастолической функции левого желудочка по "гипертрофическом" типа
NZ600486A (en) Pirfenidone treatment for patients with atypical liver function
PH12012502185A1 (en) Association of xanthine oxidase inhibitors and statins and use thereof
UA56130U (ru) Способ лечения и профилактики телязиоза
Ustun Gynaecomastia: case report

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: GEMPHIRE THERAPEUTICS, INC.

FG Grant or registration